Partnership hopes to champion diversity, inclusivity, and innovation within the clinical trials sector.
Partnering with a mission to champion diversify within the clinical trials sector, The Association of Diversity in Clinical Trials (AOD) has inked an agreement to partner with BlueCloud by HealthCarePoint.com. According to a company press release, BlueCloud’s main objective is to improve clinical research efficiency while prioritizing patient well-being.
"We enthusiastically welcome BlueCloud by HealthCarePoint.com to our community," stated Diana Foster, President, AOD. "Their innovative approach seamlessly aligns with our dedication to fostering inclusivity and equality in clinical trials. Together, we're reshaping the clinical research landscape, ensuring each patient's viewpoint and experience is valued and considered."
Reference: Association of Diversity in Clinical Trials Welcomes BlueCloud by HealthCarePoint.com as a Supporting Partner. PR Newswire. September 12, 2023. Accessed September 12, 2023. https://www.prnewswire.com/news-releases/association-of-diversity-in-clinical-trials-welcomes-bluecloud-by-healthcarepointcom-as-a-supporting-partner-301922885.html
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.